D

Diagnos Laboratorium Utama PT Tbk
IDX:DGNS

Watchlist Manager
Diagnos Laboratorium Utama PT Tbk
IDX:DGNS
Watchlist
Price: 298 IDR -1.32%
Market Cap: Rp372.5B

Diagnos Laboratorium Utama PT Tbk
Other

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Diagnos Laboratorium Utama PT Tbk
Other Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other CAGR 3Y CAGR 5Y CAGR 10Y
D
Diagnos Laboratorium Utama PT Tbk
IDX:DGNS
Other
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Prodia Widyahusada Tbk PT
IDX:PRDA
Other
-Rp4.3B
CAGR 3-Years
N/A
CAGR 5-Years
-432%
CAGR 10-Years
N/A
No Stocks Found

Diagnos Laboratorium Utama PT Tbk
Glance View

Market Cap
372.5B IDR
Industry
Health Care

PT Diagnos Laboratorium Utama Tbk engages in the provision of health support service. The company employs 54 full-time employees The company went IPO on 2021-01-15. The firm is engaged in providing health support services, such as health laboratories, other diagnostic drawing centers, blood testing laboratories, pharmaceutical warehouses, eye banks, sperm banks and blood banks, organ transplant banks, and other medical support services. The company operates through providing health services using laboratories segment. The Company’s products and services include clinical pathology laboratory, anatomy pathology laboratory, genomic laboratory, homecare health services, corporate health services, and Covid-19 checkup. The firm serves markets, such as Jakarta, Depok, Bali, Bandung, Bekasi, Padang, Makassar, Tangerang Selatan, Dumai, Batam, Purwakarta, Karawang, and Brebes. The company has branch offices in Ciputat (South Tangerang), Denpasar (Bali), Padang (West Sumatra), and Makassar, South Sulawesi.

DGNS Intrinsic Value
242.48 IDR
Overvaluation 19%
Intrinsic Value
Price
D

See Also

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett